Navigation Links
Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder
Date:11/6/2008

WALTHAM, Mass., Nov. 6 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Company has initiated a Phase 2b clinical trial to evaluate the use of RG2417, an oral formulation of uridine, in patients with bipolar depression. This Phase 2b study is a multi-center, randomized, double-blind, placebo-controlled clinical trial in which approximately 150 patients with bipolar depression will receive either RG2417 or placebo twice daily for eight weeks. This study is designed to assess the safety and efficacy of RG2417 as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression of Change in Bipolar Disorder Scale (CGI-BP-C). The study will be conducted at approximately 20 clinical sites within the United States. The Principal Investigator of this study is Gary S. Sachs, M.D., founder and director of the Bipolar Clinic and Research Program at the Massachusetts General Hospital and an Associate Professor of Psychiatry at the Harvard Medical School.

"Episodes of depression are the most frequent and long-lived symptom of bipolar disorder and account for the majority of the disease impairment. Current therapies used to treat bipolar depression are often ineffective and may have significant side effects, resulting in bipolar depression as an area of high unmet medical need," said Walter C. Herlihy, President and Chief Executive Officer of Repligen. "We look forward to confirming our prior results with RG2417 in bipolar depression in this larger proof-of-concept clinical trial."

The trial is designed to confirm and extend the results obtained in a positive Phase 2a clinical trial of RG2417 in which 83 patients with bipolar disorder received either RG2417 or place
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Repligen Reports Second Quarter Fiscal Year 2008 Financial Results
2. Repligen to Present at Upcoming Healthcare Conferences Wednesday, November 28th and Wednesday, December 5th
3. Repligen Elects Earl Henry, M.D. to the Board of Directors
4. Repligen Announces Conference Call to Update Orencia(R) Lawsuit
5. Repligen Announces Share Repurchase Program
6. Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors
7. Repligen Announces Conference Call of Second Quarter Fiscal Year 2009 Results Thursday, November 6th, 10:00 a.m. EST
8. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
9. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
10. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
11. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... United Theological Seminary is pleased to announce ... Master of Theological Studies (MTS). , This ... for students who wish to pursue further academic study of ... serve the Church and community. Previously, students needed to be ... attend classes from any location where there is an internet ...
(Date:8/30/2014)... 30, 2014 Hands On ... which offers the complete spa experience combining elegant ... and the most important ingredient of all, states ... licensed pro's! People will enjoy the get-away feel, ... The website reads, "Step into the spacious, luxurious ...
(Date:8/30/2014)... 2014 Patients suffering from vitiligo can ... a new review published by Daily Gossip. , ... so there is no wonder that numerous sufferers search ... Vitiligo Treatment is one of the most appreciated such ... promises to stop the spread of this disorder immediately, ...
(Date:8/30/2014)... Daily Gossip reveals in its review a program created ... who shows a unique formula to get inside a man’s ... that the program goes beyond mere attraction and actually helps ... indicates that the program was created by dating expert Alex ... to make a man feel emotionally addicted. , Learn more ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Daily Gossip ... that keeps anxiety and panic attacks under control with ... Away" program review describes this new method as ... control panic attacks and overcome general anxiety related disorders. ... successful is the fact that it can be accessed ...
Breaking Medicine News(10 mins):Health News:United Theological Seminary Announces First Fully Online Degree 2Health News:Hands On Mobile Massage and Spa of Long Island Now Offers a Spa-on-wheels 2Health News:Natural Vitiligo Treatment Review Exposes Fast Method for Skin Repigmentation 2Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2
... Solutions for Medical Equipment, Building Infrastructure and Automation, ... NEW YORK, March 23 Via Christi Health ... a wide range of technology and service solutions ... Christi Health System,s strategic plan.(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO ...
... Siemens Financial Services, Inc. announced today that ... to El Camino Hospital in Mountain View, California. ... a variety of Siemens Medical Solutions equipment which ... hospital under construction.(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )"For more ...
... Education Virtual Lecture for Healthcare ProfessionalsVOORHEES, N.J., March ... infection (CDI) is changing rapidly and has ... and severity. Management of CDI can be challenging ... updated. In order to effectively implement key strategies ...
... WASHINGTON, March 23 March 22 was World Water ... of the 1992 United Nations Conference on Environment and ... of World Water Day this year is Transboundary Waters: ... the Poor Act of 2005 makes access to safe ...
... MBF Healthwatch survey has revealed that a disturbing number of ... they are ,too tired, or ,can,t be bothered, having a ... 22% of parents interviewed said their children skip breakfast on ... further 20% skip breakfast on one or two school days. ...
... get relief from their symptoms and the psychological distress ... , Skin experts and psychologists at The University of ... known as ,electronic Targeted Intervention for Psoriasis, or eTIPS ... better. , "Psoriasis is a skin disease that usually ...
Cached Medicine News:Health News:Via Christi Health System and Siemens Announce Technology Alliance 2Health News:Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital 2Health News:Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital 3Health News:Clostridium difficile Infection in Primary Care: Tackling a Virulent Pathogen 2Health News:USAID World Water Day Statement 2Health News:USAID World Water Day Statement 3Health News:School kids 'wagging' breakfast are missing healthy brain fuel 2Health News:Experts turn to Web to combat distressing skin disease 2
(Date:8/30/2014)...  Boston Scientific has released the primary endpoint ... Failure (NECTAR-HF) clinical trial, the first and only ... (VNS) for the treatment of heart failure patients.  ... Cardiology and Director of the Clinical Investigation Center ... de la Recherche Medicale presented the results at ...
(Date:8/30/2014)... 2014   Royal Philips  (NYSE: PHG, AEX: PHIA) ... new ultrasound system designed to enable global hospitals and ... volumes and cost pressures. Making its debut at the  ... Barcelona this week, Affiniti provides innovative ... fewer resources deliver high quality patient care. ...
(Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- Market Research Report on Global ... a professional and in-depth market survey on ... The report firstly reviews the basic information of ... manufacturing technology. The report then explores global and ... their product specification, capacity, Production value, and market ...
Breaking Medicine Technology:Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 2Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 3Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 4Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5
... - Inovio Biomedical,Corporation (AMEX:INO), focused on the ... diseases and a novel alternative to,surgery to ... partner, Vical Incorporated, presented positive interim,safety and ... ongoing Phase I,clinical trial using Inovio's electroporation ...
... Clinical results from a,Phase II study presented ... Society (AHS) annual meeting showed that MK-0974, ... significantly improved migraine pain relief,two hours after ... was,sustained through 24 hours. MK-0974 was generally ...
Cached Medicine Technology:Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 2Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 3Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 4Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 5Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 2Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 3Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 4Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 5
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: